Vertex Pharmaceuticals
VRTX
1,497 hedge funds and large institutions have $98B invested in Vertex Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 173 funds opening new positions, 611 increasing their positions, 519 reducing their positions, and 96 closing their positions.
80% more first-time investments, than exits
New positions opened: 173 | Existing positions closed: 96
18% more repeat investments, than reductions
Existing positions increased: 611 | Existing positions reduced: 519
4% more funds holding
Funds holding: 1,441 → 1,497 (+56)
0.51% less ownership
Funds ownership: 91.66% → 91.15% (-0.51%)
3% less capital inflows, than outflows
Capital inflows: $6.18B | Capital outflows: $6.39B
7% less call options, than puts
Call options by funds: $718M | Put options by funds: $774M
29% less funds holding in top 10
Funds holding in top 10: 42 → 30 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.59B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$920M |
| 3 |
Amundi
Paris,
France
|
+$366M |
| 4 |
Jennison Associates
New York
|
+$354M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$176M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$975M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$589M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$391M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$347M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$283M |
VRTX Hedge Fund Activity: Q1 2024 in Review
1,497 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2024, worth a combined $98B — up 2.3% from $95.8B a quarter earlier.
Buyers outnumbered sellers: 173 funds opened new VRTX positions and 96 closed out — a net gain of 77 holders — while 611 added to existing stakes and 519 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.59B. The largest seller was Fidelity Investments, cutting an estimated $975M.
- 1,497 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2024, up from 1,441 in Q4 2023.
- Funds reported $98B of Vertex Pharmaceuticals stock for Q1 2024, up 2.3% quarter-over-quarter.
- 173 funds opened new Vertex Pharmaceuticals positions in Q1 2024 and 96 closed out, a net change of +77 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2024 was Capital World Investors, an estimated $1.59B added.
- The largest Vertex Pharmaceuticals seller in Q1 2024 was Fidelity Investments, an estimated $975M sold.
Based on aggregated 13F filings for Q1 2024.